Role of Epidermal Growth Factor Receptor Inhibitors in Epidermal Growth Factor Receptor Wild-Type Non–Small-Cell Lung Cancer

Worldwide, the majority of patients with advanced non–small-cell lung cancer (NSCLC) do not have activating mutations in the tyrosine kinase domain of the epidermal growth factor receptor (EGFR). These wild-type patients comprise a significant proportion of those treated with inhibitors of this path...

Full description

Saved in:
Bibliographic Details
Published inJournal of clinical oncology Vol. 31; no. 8; pp. 1061 - 1069
Main Authors Laurie, Scott A., Goss, Glenwood D.
Format Journal Article
LanguageEnglish
Published United States American Society of Clinical Oncology 10.03.2013
Subjects
Antineoplastic Agents - therapeutic use
Biomarkers, Tumor - genetics
Carcinoma, Non-Small-Cell Lung - drug therapy
Carcinoma, Non-Small-Cell Lung - genetics
Clinical Trials as Topic
Disease-Free Survival
Humans
Lung Neoplasms - drug therapy
Lung Neoplasms - genetics
Mutation
Platinum Compounds - therapeutic use
Predictive Value of Tests
Prognosis
Receptor, Epidermal Growth Factor - antagonists & inhibitors
Receptor, Epidermal Growth Factor - genetics
Online AccessGet full text

Cover

Abstract Worldwide, the majority of patients with advanced non–small-cell lung cancer (NSCLC) do not have activating mutations in the tyrosine kinase domain of the epidermal growth factor receptor (EGFR). These wild-type patients comprise a significant proportion of those treated with inhibitors of this pathway, and data from randomized trials suggest that some of these wild-type patients will derive a modest benefit from these agents. Although the detection of an activating mutation predicts for a greater likelihood of response and longer progression-free survival from an EGFR tyrosine kinase inhibitor, currently there are no biomarkers that consistently and reproducibly predict for lack of benefit in wild-type patients. Several strategies to increase the efficacy of these inhibitors in wild-type NSCLC are the subject of ongoing investigations.
AbstractList Worldwide, the majority of patients with advanced non-small-cell lung cancer (NSCLC) do not have activating mutations in the tyrosine kinase domain of the epidermal growth factor receptor (EGFR). These wild-type patients comprise a significant proportion of those treated with inhibitors of this pathway, and data from randomized trials suggest that some of these wild-type patients will derive a modest benefit from these agents. Although the detection of an activating mutation predicts for a greater likelihood of response and longer progression-free survival from an EGFR tyrosine kinase inhibitor, currently there are no biomarkers that consistently and reproducibly predict for lack of benefit in wild-type patients. Several strategies to increase the efficacy of these inhibitors in wild-type NSCLC are the subject of ongoing investigations.Worldwide, the majority of patients with advanced non-small-cell lung cancer (NSCLC) do not have activating mutations in the tyrosine kinase domain of the epidermal growth factor receptor (EGFR). These wild-type patients comprise a significant proportion of those treated with inhibitors of this pathway, and data from randomized trials suggest that some of these wild-type patients will derive a modest benefit from these agents. Although the detection of an activating mutation predicts for a greater likelihood of response and longer progression-free survival from an EGFR tyrosine kinase inhibitor, currently there are no biomarkers that consistently and reproducibly predict for lack of benefit in wild-type patients. Several strategies to increase the efficacy of these inhibitors in wild-type NSCLC are the subject of ongoing investigations.
Worldwide, the majority of patients with advanced non–small-cell lung cancer (NSCLC) do not have activating mutations in the tyrosine kinase domain of the epidermal growth factor receptor (EGFR). These wild-type patients comprise a significant proportion of those treated with inhibitors of this pathway, and data from randomized trials suggest that some of these wild-type patients will derive a modest benefit from these agents. Although the detection of an activating mutation predicts for a greater likelihood of response and longer progression-free survival from an EGFR tyrosine kinase inhibitor, currently there are no biomarkers that consistently and reproducibly predict for lack of benefit in wild-type patients. Several strategies to increase the efficacy of these inhibitors in wild-type NSCLC are the subject of ongoing investigations.
Author Glenwood D. Goss
Scott A. Laurie
Author_xml – sequence: 1
  givenname: Scott A.
  surname: Laurie
  fullname: Laurie, Scott A.
  organization: All authors: Ottawa Hospital Cancer Centre, University of Ottawa, Ottawa, Ontario, Canada
– sequence: 2
  givenname: Glenwood D.
  surname: Goss
  fullname: Goss, Glenwood D.
  organization: All authors: Ottawa Hospital Cancer Centre, University of Ottawa, Ottawa, Ontario, Canada
BackLink https://www.ncbi.nlm.nih.gov/pubmed/23401452$$D View this record in MEDLINE/PubMed
BookMark eNqFkc1O3DAUha2KCgbKvqvKq6qbDP5PWKKIX41AAqp2ZznODWOUsVM7I8Sm4h14Q54ERwObLsrqnsV3ro7O2UVbPnhA6Cslc8oIObior-aMUDYXfC4kY5_QjEpWFmUp5RaakZKzglb89w7aTemeECoqLrfRDuMia8lm6O916AGHDh8ProW4Mj0-jeFhXOITY8cQ8TVYGCZx7peucVkl7PzH-C_Xt8Xt4wD4MviXp-ebzPZFDX2PF2t_h2vjLcQv6HNn-gT7b3cP_Tw5vq3PisXV6Xl9tCgsP1RjYbgRQE1TAZWqE6y1pbANNJbITtpWiWqqo7VEQKuqsgXeSNkZCrJrbKkavod-bP4OMfxZQxr1yiWbwxgPYZ005VQRqZhiGf32hq6bFbR6iG5l4qN-7ywDagPYGFKK0GnrRjO64MdoXK8p0VMancfR0zhacD2Nk43kH-P77_9Yvm8sS3e3fHARdJp6zNGYvreBU11ls6L8FXwjoAw
CitedBy_id crossref_primary_10_1097_MD_0000000000007732
crossref_primary_10_1097_COC_0000000000000179
crossref_primary_10_1371_journal_pone_0081975
crossref_primary_10_1016_j_neo_2016_02_005
crossref_primary_10_1097_CM9_0000000000000823
crossref_primary_10_1200_JCO_2013_50_8705
crossref_primary_10_1186_1756_9966_33_15
crossref_primary_10_18632_oncotarget_15726
crossref_primary_10_3892_ol_2017_6118
crossref_primary_10_1159_000440941
crossref_primary_10_1007_s11523_015_0415_4
crossref_primary_10_1134_S000629791313004X
crossref_primary_10_1517_14656566_2016_1109635
crossref_primary_10_3109_07357907_2015_1024318
crossref_primary_10_3390_microarrays2040318
crossref_primary_10_1371_journal_pone_0240633
crossref_primary_10_1007_s11523_014_0329_6
crossref_primary_10_18632_oncotarget_1891
crossref_primary_10_18632_oncotarget_2102
crossref_primary_10_1186_s40880_018_0290_3
crossref_primary_10_1016_j_lungcan_2014_03_026
crossref_primary_10_1016_j_cancergen_2014_12_002
crossref_primary_10_1007_s00280_015_2740_9
crossref_primary_10_1007_s12253_018_0404_x
crossref_primary_10_1093_bioinformatics_btw010
crossref_primary_10_3390_jpm7030005
crossref_primary_10_1016_j_freeradbiomed_2015_07_155
crossref_primary_10_1186_s13045_014_0070_8
crossref_primary_10_1038_oncsis_2016_61
crossref_primary_10_1517_17460441_2013_843523
crossref_primary_10_1093_carcin_bgx079
crossref_primary_10_1158_1535_7163_MCT_13_0951
crossref_primary_10_1016_j_biopha_2017_02_097
crossref_primary_10_1038_nbt_2732
crossref_primary_10_1016_j_lungcan_2018_06_013
crossref_primary_10_1038_cddis_2015_217
crossref_primary_10_1186_s13062_015_0046_9
crossref_primary_10_3390_ijms16010747
crossref_primary_10_1038_onc_2016_465
crossref_primary_10_1093_annonc_mdy196
crossref_primary_10_18632_oncotarget_4254
crossref_primary_10_1111_ajco_12231
crossref_primary_10_1038_s41598_020_63200_7
crossref_primary_10_4046_trd_2018_0004
crossref_primary_10_1186_1476_4598_13_252
crossref_primary_10_1016_j_jmoldx_2019_06_010
crossref_primary_10_1200_JCO_2013_52_4694
crossref_primary_10_2217_lmt_13_39
crossref_primary_10_1111_jcmm_14085
crossref_primary_10_3389_fimmu_2020_00071
crossref_primary_10_1038_srep18566
crossref_primary_10_3390_biomedicines8080273
crossref_primary_10_1016_j_ijrobp_2013_09_007
crossref_primary_10_1039_D3NJ03204C
crossref_primary_10_1634_theoncologist_2015_0209
crossref_primary_10_3389_fonc_2022_805538
crossref_primary_10_3892_ijo_2015_2898
crossref_primary_10_1200_JCO_2013_50_2617
crossref_primary_10_18632_oncotarget_20281
crossref_primary_10_1093_bib_bbaa294
crossref_primary_10_1002_14651858_CD012901
crossref_primary_10_1016_j_rmr_2019_03_010
crossref_primary_10_1002_cam4_2492
crossref_primary_10_1186_s40360_023_00661_2
crossref_primary_10_1007_s11523_015_0376_7
crossref_primary_10_1200_JCO_2012_47_5772
crossref_primary_10_1586_17512433_2013_841540
crossref_primary_10_1177_1758834013492001
crossref_primary_10_1016_S1470_2045_13_70310_3
crossref_primary_10_1002_ijc_28925
Cites_doi 10.1093/annonc/mdp506
10.1200/JCO.2003.10.038
10.1056/NEJMoa050736
10.1200/JCO.2006.06.3958
10.1200/JCO.2000.18.10.2095
10.1016/j.cct.2008.01.004
10.1016/j.lungcan.2004.07.047
10.1097/JTO.0b013e31824166c1
10.1200/JCO.2009.21.9618
10.1200/jco.2012.30.4_suppl.480
10.1016/S0140-6736(09)61497-5
10.1200/JCO.2004.08.001
10.1002/jcp.21635
10.1200/JCO.2007.13.2720
10.1200/jco.2010.28.18_suppl.lba7523
10.1200/jco.2012.30.18_suppl.lba7501
10.1016/S1470-2045(11)70189-9
10.1200/JCO.2004.11.057
10.1200/jco.2010.28.15_suppl.7508
10.1016/S1470-2045(12)70087-6
10.1200/JCO.2010.31.0805
10.1056/NEJMoa0904554
10.1200/JCO.2005.05.1474
10.1158/0008-5472.CAN-06-1684
10.1200/JCO.2007.15.0672
10.1200/JCO.2004.08.163
10.1158/1078-0432.CCR-10-2525
10.1200/JCO.2009.25.2890
10.1126/science.1141478
10.1038/nrc1609
10.1097/JTO.0b013e3181fb4fe2
10.1001/jama.290.16.2149
10.1200/JCO.2005.02.840
10.1016/S1470-2045(11)70385-0
10.1097/JTO.0b013e31823a39e8
10.1016/S1470-2045(10)70278-3
10.1200/JCO.2011.36.8456
10.1200/JCO.2010.31.8162
10.1200/JCO.2009.27.4365
10.1200/JCO.2008.18.4408
10.1093/jnci/dji112
10.1200/JCO.2004.07.215
10.1200/JCO.2007.14.8924
10.1016/S0140-6736(11)60780-0
10.1016/S0140-6736(09)60569-9
10.1016/j.ejca.2011.06.045
10.1038/onc.2010.219
10.1200/JCO.2011.39.7646
10.1056/NEJMoa0810699
10.1016/S1470-2045(11)70318-7
10.1200/jco.2012.30.15_suppl.7506
10.1056/NEJMoa050753
10.1200/jco.2011.29.15_suppl.7533
10.1016/S1470-2045(10)70112-1
10.1016/S0140-6736(05)67625-8
10.1097/JTO.0b013e31820a0ec0
10.1016/j.tcb.2006.10.008
10.1093/annonc/mdi279
10.1200/JCO.2011.36.6799
10.1200/jco.2011.29.15_suppl.7505
10.1007/s10555-010-9201-z
10.1200/JCO.2010.34.0570
10.1016/S0140-6736(08)61758-4
10.1200/JCO.2009.24.3030
10.1016/S1470-2045(08)70206-7
ContentType Journal Article
DBID AAYXX
CITATION
CGR
CUY
CVF
ECM
EIF
NPM
7X8
DOI 10.1200/JCO.2012.43.4522
DatabaseName CrossRef
Medline
MEDLINE
MEDLINE (Ovid)
MEDLINE
MEDLINE
PubMed
MEDLINE - Academic
DatabaseTitle CrossRef
MEDLINE
Medline Complete
MEDLINE with Full Text
PubMed
MEDLINE (Ovid)
MEDLINE - Academic
DatabaseTitleList MEDLINE - Academic
CrossRef
MEDLINE
Database_xml – sequence: 1
  dbid: NPM
  name: PubMed
  url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed
  sourceTypes: Index Database
– sequence: 2
  dbid: EIF
  name: MEDLINE
  url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search
  sourceTypes: Index Database
DeliveryMethod fulltext_linktorsrc
Discipline Medicine
Pharmacy, Therapeutics, & Pharmacology
EISSN 1527-7755
EndPage 1069
ExternalDocumentID 23401452
10_1200_JCO_2012_43_4522
jco31_8_1061
Genre Research Support, Non-U.S. Gov't
Journal Article
Review
GroupedDBID -
0R
2WC
34G
39C
4.4
53G
55
5GY
5RE
8F7
AAPEM
AARDX
AAWTL
AAYEP
ABFLS
ABOCM
ACDCL
ACGFS
ADBBV
ADKWQ
AENEX
ALMA_UNASSIGNED_HOLDINGS
AWKKM
BAWUL
CS3
DIK
EBD
EBS
EJD
F5P
FD8
FH7
GX1
H13
HZ
IH2
K-O
KQ8
L7B
LSO
N9A
O9-
OK1
OVD
OWW
P2P
RHI
RUC
SJN
SV3
TWZ
UDS
WH7
X7M
YCJ
ZA5
---
.55
0R~
18M
AAYOK
AAYXX
ABBLC
ABJNI
ACGFO
ACGUR
AEGXH
AIAGR
C45
CITATION
F9R
FBNNL
HZ~
MJL
QTD
R1G
RLZ
TEORI
TR2
VVN
YFH
YQY
CGR
CUY
CVF
ECM
EIF
NPM
7X8
ID FETCH-LOGICAL-c396t-a3a4e1ab8e156f42dc74cbebc05f5cd6481200dc04ed687de3b55fa1e5fbc76b3
ISSN 0732-183X
1527-7755
IngestDate Thu Jul 10 17:28:24 EDT 2025
Thu Apr 03 07:05:47 EDT 2025
Tue Jul 01 01:11:40 EDT 2025
Thu Apr 24 23:09:20 EDT 2025
Tue Jan 05 20:16:30 EST 2021
IsPeerReviewed true
IsScholarly true
Issue 8
Language English
LinkModel OpenURL
MergedId FETCHMERGED-LOGICAL-c396t-a3a4e1ab8e156f42dc74cbebc05f5cd6481200dc04ed687de3b55fa1e5fbc76b3
Notes ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
ObjectType-Review-3
content type line 23
PMID 23401452
PQID 1316056262
PQPubID 23479
PageCount 9
ParticipantIDs proquest_miscellaneous_1316056262
pubmed_primary_23401452
crossref_citationtrail_10_1200_JCO_2012_43_4522
crossref_primary_10_1200_JCO_2012_43_4522
highwire_smallpub2_jco31_8_1061
ProviderPackageCode RHI
CITATION
AAYXX
PublicationCentury 2000
PublicationDate 20130310
2013-03-10
2013-Mar-10
PublicationDateYYYYMMDD 2013-03-10
PublicationDate_xml – month: 03
  year: 2013
  text: 20130310
  day: 10
PublicationDecade 2010
PublicationPlace United States
PublicationPlace_xml – name: United States
PublicationTitle Journal of clinical oncology
PublicationTitleAlternate J Clin Oncol
PublicationYear 2013
Publisher American Society of Clinical Oncology
Publisher_xml – name: American Society of Clinical Oncology
References B20
B64
B21
B65
B22
B23
B67
B24
Perol M (B35) 2010; 21
B68
B25
B26
B27
B28
B29
Paz-Ares L (B44) 2012; 30
B30
B31
B32
B33
Miller VA (B34) 2009; 27
B36
B37
B38
B39
B1
B2
B3
B4
B5
B6
B7
B8
B9
Kim ES (B40) 2012; 30
B41
B43
B45
B46
B47
B49
B50
B51
B52
B53
B10
B54
B11
B55
B12
B56
B13
B57
B14
B58
B15
Ruschoff J (B48) 2011; 6
B59
B16
B17
B18
B19
Lilenbaum R (B42) 2012; 30
B60
B61
B62
B63
23943831 - J Clin Oncol. 2013 Sep 10;31(26):3293-4
23940223 - J Clin Oncol. 2013 Sep 10;31(26):3291-3
References_xml – volume: 21
  start-page: 370PD
  year: 2010
  ident: B35
  publication-title: Ann Oncol
  doi: 10.1093/annonc/mdp506
– ident: B10
  doi: 10.1200/JCO.2003.10.038
– ident: B15
  doi: 10.1056/NEJMoa050736
– ident: B16
  doi: 10.1200/JCO.2006.06.3958
– ident: B46
  doi: 10.1200/JCO.2000.18.10.2095
– ident: B58
  doi: 10.1016/j.cct.2008.01.004
– ident: B9
  doi: 10.1016/j.lungcan.2004.07.047
– ident: B53
  doi: 10.1097/JTO.0b013e31824166c1
– ident: B29
  doi: 10.1200/JCO.2009.21.9618
– volume: 30
  start-page: 480s
  year: 2012
  ident: B40
  publication-title: J Clin Oncol
  doi: 10.1200/jco.2012.30.4_suppl.480
– ident: B43
  doi: 10.1016/S0140-6736(09)61497-5
– ident: B26
  doi: 10.1200/JCO.2004.08.001
– ident: B7
  doi: 10.1002/jcp.21635
– ident: B19
  doi: 10.1200/JCO.2007.13.2720
– ident: B60
  doi: 10.1200/jco.2010.28.18_suppl.lba7523
– ident: B23
  doi: 10.1200/jco.2012.30.18_suppl.lba7501
– ident: B18
  doi: 10.1016/S1470-2045(11)70189-9
– ident: B12
  doi: 10.1200/JCO.2004.11.057
– ident: B32
  doi: 10.1200/jco.2010.28.15_suppl.7508
– ident: B59
  doi: 10.1016/S1470-2045(12)70087-6
– volume: 27
  start-page: 407s
  year: 2009
  ident: B34
  publication-title: J Clin Oncol
– ident: B54
  doi: 10.1200/JCO.2010.31.0805
– ident: B2
  doi: 10.1056/NEJMoa0904554
– ident: B28
  doi: 10.1200/JCO.2005.05.1474
– ident: B64
  doi: 10.1158/0008-5472.CAN-06-1684
– ident: B20
  doi: 10.1200/JCO.2007.15.0672
– ident: B45
  doi: 10.1200/JCO.2004.08.163
– ident: B68
  doi: 10.1158/1078-0432.CCR-10-2525
– ident: B30
  doi: 10.1200/JCO.2009.25.2890
– ident: B61
  doi: 10.1126/science.1141478
– ident: B5
  doi: 10.1038/nrc1609
– ident: B3
  doi: 10.1097/JTO.0b013e3181fb4fe2
– ident: B11
  doi: 10.1001/jama.290.16.2149
– ident: B27
  doi: 10.1200/JCO.2005.02.840
– ident: B39
  doi: 10.1016/S1470-2045(11)70385-0
– ident: B21
  doi: 10.1097/JTO.0b013e31823a39e8
– volume: 6
  start-page: S1032
  year: 2011
  ident: B48
  publication-title: J Thorac Oncol
– ident: B57
  doi: 10.1016/S1470-2045(10)70278-3
– ident: B31
  doi: 10.1200/JCO.2011.36.8456
– ident: B52
  doi: 10.1200/JCO.2010.31.8162
– ident: B50
  doi: 10.1200/JCO.2009.27.4365
– ident: B22
  doi: 10.1200/JCO.2008.18.4408
– ident: B49
  doi: 10.1093/jnci/dji112
– ident: B25
  doi: 10.1200/JCO.2004.07.215
– ident: B24
  doi: 10.1200/JCO.2007.14.8924
– ident: B41
  doi: 10.1016/S0140-6736(11)60780-0
– ident: B17
  doi: 10.1016/S0140-6736(09)60569-9
– ident: B36
  doi: 10.1016/j.ejca.2011.06.045
– ident: B67
  doi: 10.1038/onc.2010.219
– volume: 30
  start-page: 481s
  year: 2012
  ident: B44
  publication-title: J Clin Oncol
  doi: 10.1200/JCO.2011.39.7646
– ident: B4
  doi: 10.1056/NEJMoa0810699
– ident: B47
  doi: 10.1016/S1470-2045(11)70318-7
– volume: 30
  start-page: 481s
  year: 2012
  ident: B42
  publication-title: J Clin Oncol
  doi: 10.1200/jco.2012.30.15_suppl.7506
– ident: B13
  doi: 10.1056/NEJMoa050753
– ident: B55
  doi: 10.1200/jco.2011.29.15_suppl.7533
– ident: B33
  doi: 10.1016/S1470-2045(10)70112-1
– ident: B14
  doi: 10.1016/S0140-6736(05)67625-8
– ident: B1
  doi: 10.1097/JTO.0b013e31820a0ec0
– ident: B6
  doi: 10.1016/j.tcb.2006.10.008
– ident: B56
  doi: 10.1093/annonc/mdi279
– ident: B65
  doi: 10.1200/JCO.2011.36.6799
– ident: B63
  doi: 10.1200/jco.2011.29.15_suppl.7505
– ident: B8
  doi: 10.1007/s10555-010-9201-z
– ident: B62
  doi: 10.1200/JCO.2010.34.0570
– ident: B37
  doi: 10.1016/S0140-6736(08)61758-4
– ident: B38
  doi: 10.1200/JCO.2009.24.3030
– ident: B51
  doi: 10.1016/S1470-2045(08)70206-7
– reference: 23940223 - J Clin Oncol. 2013 Sep 10;31(26):3291-3
– reference: 23943831 - J Clin Oncol. 2013 Sep 10;31(26):3293-4
SSID ssj0014835
Score 2.3833568
SecondaryResourceType review_article
Snippet Worldwide, the majority of patients with advanced non–small-cell lung cancer (NSCLC) do not have activating mutations in the tyrosine kinase domain of the...
Worldwide, the majority of patients with advanced non-small-cell lung cancer (NSCLC) do not have activating mutations in the tyrosine kinase domain of the...
SourceID proquest
pubmed
crossref
highwire
SourceType Aggregation Database
Index Database
Enrichment Source
Publisher
StartPage 1061
SubjectTerms Antineoplastic Agents - therapeutic use
Biomarkers, Tumor - genetics
Carcinoma, Non-Small-Cell Lung - drug therapy
Carcinoma, Non-Small-Cell Lung - genetics
Clinical Trials as Topic
Disease-Free Survival
Humans
Lung Neoplasms - drug therapy
Lung Neoplasms - genetics
Mutation
Platinum Compounds - therapeutic use
Predictive Value of Tests
Prognosis
Receptor, Epidermal Growth Factor - antagonists & inhibitors
Receptor, Epidermal Growth Factor - genetics
Title Role of Epidermal Growth Factor Receptor Inhibitors in Epidermal Growth Factor Receptor Wild-Type Non–Small-Cell Lung Cancer
URI http://jco.ascopubs.org/content/31/8/1061.abstract
https://www.ncbi.nlm.nih.gov/pubmed/23401452
https://www.proquest.com/docview/1316056262
Volume 31
hasFullText 1
inHoldings 1
isFullTextHit
isPrint
link http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV1Zb9QwELagSIgXBOVaTiOhSmib7cZ2jn1Ey1FApRVspb5Z8RFaFJJVN_tQxI9nJnaSLupS4CWKHMeW_H2ZzNhzEPJCq2zCVWSDzE5MIHQuglRl4wB042TC0oyrEOOd9z7Fu4fiw1F01PvPN9EltRrpHxfGlfwPqtAGuGKU7D8g2w0KDXAP-MIVEIbrX2H82bsGWizzChK2GH4Fq7o-9lV0hiDN7LxuPM6PT9RJU1gHU4Rc1h30ZxM0m7NlVQYL6FkEuMM_LJYYootEOV2j1XaRllWpV3bsMQDbnYV8adJBdMx519ZtL5wDkPdB9jsRWBUC3drcj8RLT5aAuu7y7rbi1Qt5R6P0nKxEY_RCIc5cferpPnresZHgI0z7fr4rwDD_3oDKuMCDUdb_zjonw_bRVXKNgQ2B5S1ev__YHTEJ0D39uTVMuPP7dJgl2g-wqrK0aaTXmySNajK7RW761aevHEFukyu23CTX97zXxCbZOnD5yc-26awPt1ts0y160GcuP7tDfiKhaJXTjiHUMYQ6htCWIbQnFNxe3r0jFF0lFEVCUUeou-Tw7ZvZdDfw5TkCzSdxHWQ8EzbMVGrDKM4FMzoRWlmlx1EeaROLFBfW6LGwJk4TY0EmRHkW2ihXOokVv0c2YFL7gFAdQitnqcknVhhhM2FMJGCoHASHYuGA7LQISO1z12MJlUKiDcvwQHa6LxE-KbhE-AbkZffG3OVt-UPfZy2oslkBAJPJb7rioUwl0nRAnrdYSxC_uEBZaavlQoY8jNGGiGGU-44E3Xwtfx6uffKI3Og_pMdkoz5d2ieg5NbqaUPWX1krq28
linkProvider Flying Publisher
openUrl ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Role+of+epidermal+growth+factor+receptor+inhibitors+in+epidermal+growth+factor+receptor+wild-type+non-small-cell+lung+cancer&rft.jtitle=Journal+of+clinical+oncology&rft.au=Laurie%2C+Scott+A&rft.au=Goss%2C+Glenwood+D&rft.date=2013-03-10&rft.eissn=1527-7755&rft.volume=31&rft.issue=8&rft.spage=1061&rft_id=info:doi/10.1200%2FJCO.2012.43.4522&rft_id=info%3Apmid%2F23401452&rft.externalDocID=23401452
thumbnail_l http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=0732-183X&client=summon
thumbnail_m http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=0732-183X&client=summon
thumbnail_s http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=0732-183X&client=summon